TTI-622-01 (NCT03530683) is a two-part, multicenter, open-label, phase 1a/1b study in patients with advanced relapsed or refractory lymphoma or multiple myeloma. In the phase 1a dose-escalation part, lymphoma patients are being enrolled in sequential dose cohorts to receive TTI-622 once weekly to characterize safety, tolerability, pharmacokinetics, and to determine the maximum tolerated dose. In the phase 1b part, patients with hematologic malignancies will be treated with TTI-622 in combination with other agents. Emerging data from the trial indicates that TTI-622 is well tolerated and exhibits dose dependent drug exposure and target engagement. TTI-622 has also demonstrated some initial monotherapy activity.